Conflicting signals on US accelerated approvals

The results of a phase 3 clinical study on the lung cancer drug Iressa (gefitinib) have revealed that the drug did not produce a significant survival advantage over placebo. Since then some FDA critics contend that the accelerated review process should be slowed, whereas others fear that heightened anxieties about safety could undermine a program that provides therapeutics more quickly to needy patients.